Loading...

EVOFEM BIOSCIENCES INC Company Mergers 8-K Filing

VFM

EVOFEM BIOSCIENCES INC

()

2025 8-K

Distributorship Agreement

Securities Agreement Update

Agreement Termination

2025 Financial Results

Corporate Presentation Update

Annual Meeting Results

Financial Results Report

Merger Termination

Securities Purchase Amendment

Financial Results Report

Equity Offerings

Licensing Agreement

Financial Statements

Securities Agreement

License Agreement

Financial Results

External Links:

Evofem Biosciences entered into an amendment to a License and Supply Agreement with Windtree Therapeutics on March 28, 2025, clarifying terms related to the manufacturing and supply of PHEXXI, effective from March 20, 2025.

AI Assistant

EVOFEM BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.